⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 16 in last 7 days 🍎 Food: 193 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 16 in last 7 days 🍎 Food: 193 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine AT May 7, 2025

Palibon 25 mg Depot-Injektionssuspension in einer Fertigspritze 25 mg (Depot-Injektionssuspension in einer Fertigspritze)

📷 Wikipedia: Paliperidone palmitate · Source
Palibon 25 mg Depot-Injektionssuspension in einer Fertigspritze 25 mg (Depot-Injektionssuspension in einer Fertigspritze)
📷 Wikipedia: Paliperidone palmitate · Source
A ban on parallel export is in effect for Palibon 25 mg depot injection suspension in a pre-filled syringe. Manufacturing quality issues are the reason.
🗄
Archived (older alert)
This alert was reported 386 days ago and has been moved from our active feed to the archive. The original safety information still applies — we have no confirmation from the issuing agency that the product is safe again. Refer to the official notice for the current status.
📈 Timeline
10 days in total
May 18, 2026 May 28, 2026
Daily snapshot data starts accumulating once the scheduler runs — for now this is interpolated from the agency's first/last dates.

What is this? Palibon is a medicine given as a shot. It helps with mental health problems. It comes in a ready-to-use syringe.

What's happening? The medicine is not available right now. There is a problem with how it is made. It may come back in July 2026.

Does this affect me? If you take Palibon in Austria, this may affect you. Check with your doctor or pharmacist.

What should I do? Do not stop taking your medicine without asking. Talk to your pharmacist or doctor about other options.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
PALIPERIDON PALMITAT
Agency-published detail

🚫 Parallel export ban active · ATC: N05AX13 · Reason: Qualitätsprobleme bei der Herstellung · Marketing authorisation holder: G.L. Pharma GmbH, Schloßplatz 1, 8502 Lannach, Österreich · Affected packs: 1 Stück Schachtel, Fertigspritze [Nicht verfügbar, since 2025-05-07, resupply 2026-07-24]

First published
May 7, 2025
Last refreshed by us
1 week ago
Severity (as classified)
High
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

High AT 4 months ago

Palibon 75 mg Depot-Injektionssuspension in einer Fertigspritze 75 mg (Depot-Injektionssuspension in einer Fertigspritze)

Parallel export of Palibon 75 mg depot injection suspension in pre-filled syringe is banned due to manufacturing quality issues.
High AT 4 months ago

Palibon 100 mg Depot-Injektionssuspension in einer Fertigspritze 100 mg (Depot-Injektionssuspension in einer Fertigspritze)

Parallel export ban in effect. Quality manufacturing issues reported. Affected product: Palibon 100 mg depot injection suspension in pre-filled syringe. Supply unavailable since January 7, 2026; resup...
High AT 4 months ago

Palibon 50 mg Depot-Injektionssuspension in einer Fertigspritze 50 mg (Depot-Injektionssuspension in einer Fertigspritze)

Parallel export is banned for this product. It is a 50 mg depot injection suspension in a pre-filled syringe. Manufacturing quality issues have been identified. Supply is currently unavailable and exp...
High AT 4 months ago

Palibon 150 mg Depot-Injektionssuspension in einer Fertigspritze 150 mg (Depot-Injektionssuspension in einer Fertigspritze)

Parallel export is banned. The product is unavailable due to manufacturing quality issues.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Palibon 25 mg Depot-Injektionssuspension in einer Fertigspritze 25 mg (Depot-Injektionssuspension in einer Fertigspritze). A ban on parallel export is in effect for Palibon 25 mg depot injection suspension in a pre-filled syringe. Manufacturing quality issues are the reason.
▸ When was this alert issued?
This alert was issued on May 7, 2025 by BASG (Austria).
▸ Which countries are affected?
The alert applies to Austria.
▸ How serious is this alert?
Serious risk. A serious risk means the product or medicine can cause significant harm. Treat the alert as urgent.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.